Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
Vortioxetine Shows Promise in Glioblastoma Treatment by Targeting Tumor-Specific Vulnerabilities
• A high-throughput drug screening identified vortioxetine, a neuroactive drug, as a potential treatment for glioblastoma, demonstrating anti-cancer activity in patient-derived cells.
• Ex vivo drug testing revealed that vortioxetine selectively targets glioblastoma cells, reducing their viability while sparing other cell types, indicating a tumor-specific mechanism.
• Mechanistic studies showed vortioxetine modulates calcium signaling and downregulates key genes involved in glioblastoma proliferation and survival, such as BTG1 and BTG2.
• In vivo experiments in mice confirmed that vortioxetine can inhibit glioblastoma tumor growth, suggesting its potential as a novel therapeutic agent for this aggressive brain cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath